CELLTRION
24.5.2024 03:27:31 CEST | Business Wire | Press release
Celltrion today announced that the European Commission (EC) has approved Omlyclo® (CT-P39), an omalizumab biosimilar referencing Xolair®. Omlyclo® is approved for the treatment of allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP).
The EC approval of Omlyclo® follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in March 2024.
The decision is based on clinical evidence, including results from a global Phase III clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of Omlyclo® compared to the reference product Xolair® in patients with CSU up to Week 40.
“For more than two decades, omalizumab, a blockbuster monoclonal antibody anti-IgE, has revolutionised the management of chronic immune-mediated inflammatory diseases,” said Professor Marcus Maurer, Professor of Dermatology and Allergy, Co-Director for the Fraunhofer Site for Immunology and Allergology of the Fraunhofer Translational Medicine and Pharmacology ITMP and Executive Director for the Institute of Allergology, Charité - Universitätsmedizin Berlin, Germany. “The development of a biosimilar of omalizumab is a welcome solution to help alleviate some challenges with treatment access. The recently approved treatment Omlyclo® has a comparable efficacy, safety and immunogenicity profile to Xolair®.”
“Immunological conditions such as asthma can have a significant impact on the day-to-day lives of patients without appropriate treatment and care. This is why we are pleased to receive the first EC approval for an omalizumab biosimilar in Europe, an important step towards improving patient access to treatment. As we continue to expand our biosimilar offerings across the globe, building on our immunology and oncology product portfolio, we look forward to making a meaningful difference for patients living with immunological conditions,” said Hyoung-Ki Kim, Vice Chairman at Celltrion.
Omlyclo® is Celltrion’s sixth biosimilar, besides Remsima® SC, a subcutaneous formulation of infliximab, approved for use in the EU, following the approval of Remsima® (biosimilar infliximab), Truxima® (biosimilar rituximab), Herzuma® (biosimilar trastuzumab), Yuflyma® (biosimilar adalimumab), and Vegzelma® (biosimilar bevacizumab). Omlyclo® is currently under review by the U.S. Food and Drug Administration (FDA), following the submission in March 2024.
About OMLYCLO® (CT-P39, biosimilar omalizumab)
Omlyclo® is the first European Commission (EC) approved anti-IgE antibody biosimilar referencing Xolair® (omalizumab). In the EU, Omlyclo® is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP).
About Celltrion
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma® and Yuflyma®, FDA approval for Zymfentra™, and EC approval for Remsima® SC. To learn more, please visit www.celltrion.com/en-us.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion Inc. and its subsidiaries believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Trademark
Xolair® is a registered trademark of Novartis AG.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521556727/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Launches Quest Builder and Backpack, Enabling Video Game Developers to Reward Players With Items to Collect, Own, and Give Away17.11.2026 15:00:00 CET | Press release
Xsolla Expands Its Core Platform With Xsolla Quest Builder and Backpack to Help Developers and Brands Use Digital Items to Attract and Retain Players Xsolla (USA), Inc., a global commerce company, today announced the launch of Xsolla Quest Builder, a no-code tool that lets video game developers reward players with digital items for reaching goals tracked through game events, alongside Xsolla Backpack, a persistent inventory where players keep those items. Xsolla Quest Builder helps developers acquire new users, improve retention and lifetime value, and learn what players value and want in their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117128292/en/ Graphic: Xsolla Across the industry, players want more value from games and the digital items they acquire to enhance their in-game experience. To address this, along with rising user acquisition costs facing game developers, Xsolla is introducing a new way for pla
Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 15:00:00 CET | Press release
Trulioo customers can now verify identities and assess fraud risk in one integrated platform Trulioo and Bureau today announced a joint go-to-market partnership that adds Bureau’s device and behavioral intelligence, alongside its proprietary cross-business network graph intelligence for identifying connected fraud activity, to Trulioo’s global risk intelligence platform for fraud and financial crimes. Together, the companies are helping banks, fintechs, payments companies and marketplaces in APAC and the U.S. confirm who someone is and assess whether to trust them, all on one platform. AI is making fraud more complex and harder to detect, and organizations need stronger defenses to keep pace. Identity verification is only part of the picture; businesses also need to understand the risk behind every interaction, from onboarding throughout the customer journey. By partnering with Bureau, Trulioo is adding device and behavioral intelligence to its identity verification and risk signals, c
Phison Launches Purpose-Built Storage Solutions for New Space Economy17.11.2026 15:00:00 CET | Press release
New purpose-built Pascari Space storage solutions deliver mission-specific reliability, resilience and customization for spacecraft, lunar and orbital data centers Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of Pascari Space, a new category of purpose-built SSD solutions engineered for commercial outer space applications and orbital infrastructure, on display this week at the SC26 conference. Built upon Phison's decades of NAND engineering expertise and flight-proven storage heritage, Pascari Space leverages Phison IMAGIN+ customization and design services to deliver mission-specific storage solutions built to withstand the extreme demands of outer space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117623865/en/ Phison Launches Purpose-Built Storage Solutions for New Space Economy As terrestrial data infrastructure faces mounti
Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprises17.11.2026 15:00:00 CET | Press release
Turnkey system combines high-performance private AI inference, generative business intelligence and persistent enterprise storage for operational resilience Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of the Phison AI Data Platform (AIDP) with generative business intelligence (GenBI), a turnkey, sovereign AI system that will be showcased at Supercomputing 2026 (SC26) in booth #5413. Powered by Pascari aiDAPTIV ™ Cache Memory technology, Phison AIDP combines locally hosted AI models, integrated inference services, governed analytics and persistent enterprise storage to help organizations unlock business intelligence while maintaining control over their data, infrastructure and AI operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117045294/en/ Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprise
IQM unveils Halocene upgrade program at SC26, creating a path to over 1,000 qubits while accelerating integration with AI-based applications17.11.2026 15:00:00 CET | Press release
IQM Halocene, the company’s error-correction product line, now offers an upgrade path to over 1,000 qubits on the way to fault-tolerant quantum computing Built on IQM’s experience integrating and upgrading more quantum computers in HPC centers than any other company IQM’s HPC integration service, included with each upgrade, connects every new Halocene system to a center’s existing infrastructure, schedulers and GPU platforms, so it is productive from day one Upgrades without downtime, more value from each upgrade and continuity of software, workflows and skills from one system to the next New customers can start now and grow with Halocene, while existing customers can move to each new system seamlessly IQM Quantum Computers (Nasdaq: IQMX), a global leader in integrated quantum computing, today announced an upgrade program for IQM Halocene, its error-correction product line, that gives customers a path from the 150-qubit system of today to the over 1,000-qubit system of the future. Cust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
